Literature DB >> 2587945

Immune status and booster effects of low doses of diphtheria toxoid in Swedish medical personnel.

B Björkholm1, M Wahl, M Granström, L Hagberg.   

Abstract

During a diphtheria outbreak among Swedish alcoholics in 1984-1985, only 60% of 328 medical staff at risk for exposure had diphtheria antitoxin titers greater than or equal to 0.01 IU/ml, which is usually considered to give relative protection. 21% had levels between 0.01-0.09 IU/ml and the remaining 39% had titers greater than or equal to 0.1 IU/ml. Booster doses of 0.5 Lf-12.5 Lf of diphtheria toxoid were given to 450 vaccinees. Of 72 individuals with low pre-immunization titers, who were immunized with less than or equal to 2.5 Lf diphtheria toxoid, 40% failed to reach greater than or equal to 0.1 IU/ml when analyzed 4 weeks after vaccination. Local tenderness and swelling greater than 5 cm at the site of injection or general discomfort was found in 11% of those immunized with low dose diphtheria toxoid (less than or equal to 2.5 Lf). When the dose 0.5 Lf of diphtheria toxoid was combined with tetanus toxoid (3.75 Lf) the frequency of adverse reactions increased to 34% (p less than 0.001). The study shows that vaccination status in medical personnel must also be continuously examined in countries where diphtheria is rare and that low booster doses of diphtheria toxoid may not achieve an adequate immune response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2587945     DOI: 10.3109/00365548909167448

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  Immune status against diphtheria among immigrants from the former USSR who arrived in Israel during 1990-1991.

Authors:  M Low; R Almog; M S Green; S Ashkenazi; H Bercovier; E Katzenelson; I Ashkenazi; J Shemer; D Cohen
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Implications for vaccine policy.

Authors:  D Cohen; M S Green; E Katzenelson; R Slepon; H Bercovier; M Wiener
Journal:  Eur J Epidemiol       Date:  1994-06       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.